Kyverna Therapeutics, Inc. (KYTX): who owns it and who trades it
As of Nov 16, 2026, KYTX insiders reported 1 open-market sale worth $293K and 1 purchase worth $1000K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Karen Marie Walker (Chief Technology Officer), with $293K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Kyverna Therapeutics
From the latest filingsOverall: about as much buying as selling. Funds, insiders and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns KYTX
120 funds and institutions reported KYTX shares worth $338M at the end of Q2 2026, about 63% of the company. The largest holder is GordonMD Global Investments LP with 7.0%.
Funds and institutions (13F) 63%Everyone else 37%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| GordonMD Global Investments LP | 4.24M | 7.02% | $37.8M | No change |
| Gilead Sciences, Inc. | 4.13M | 6.83% | $36.8M | No change |
| BlackRock, Inc. | 3.13M | 5.19% | $27.9M | +257% |
| Bain Capital Life Sciences Investors, LLC | 2.88M | 4.77% | $25.7M | -7% |
| AIGH Capital Management LLC | 2.80M | 4.63% | $24.9M | +40% |
| Deerfield Management Company, L.P. | 2.00M | 3.31% | $17.8M | No change |
| Vanguard Capital Management LLC | 1.90M | 3.14% | $16.9M | +6% |
| T. Rowe Price Associates | 1.19M | 1.96% | $10.6M | -24% |
| Geode Capital Management, LLC | 1.05M | 1.74% | $9.4M | +148% |
| Insight Holdings Group, LLC | 989,054 | 1.64% | $8.8M | No change |
| Morgan Stanley | 982,307 | 1.63% | $8.8M | +1% |
| State Street Corp | 982,233 | 1.63% | $8.8M | +610% |
| Propel Bio Management, LLC | 883,198 | 1.46% | $7.9M | +37% |
| Woodline Partners LP | 845,325 | 1.40% | $7.5M | No change |
| Millennium Management LLC | 639,780 | 1.06% | $5.7M | -36% |
| Mbb Public Markets I LLC | 614,477 | 1.02% | $5.5M | No change |
| Adage Capital Partners Gp, L.l.c. | 500,000 | 0.83% | $4.5M | No change |
| D. E. Shaw & Co., Inc. | 469,346 | 0.78% | $4.2M | -35% |
| Wells Fargo & Company | 373,009 | 0.62% | $3.3M | +226% |
| UBS Group AG | 365,574 | 0.60% | $3.3M | -19% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, KYTX insiders reported $1000K of open-market purchases and $293K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 18, 2025 | Beth C Seidenberg | Director | Purchase | 133,333 | $7.50 | $1000K | Form 4 |
| Dec 15, 2025 | Karen Marie Walker | Chief Technology Officer | Sale | 23,998 | $12.20 | $293K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Beth C Seidenberg | Director | $1000K | – | Dec 18, 2025 |
| Karen Marie Walker | Chief Technology Officer | – | $293K | Dec 15, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
KYTX short interest
High short interest. 14.7% of KYTX shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 72%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.10M KYTX shares were sold short, 14.7% of the shares outstanding, down 4.7% from the report before. At the average daily volume of 784,251 shares, buying them all back would take about 11.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.10M | 14.71% | -5% | 784,251 | 11.6 |
| Oct 15, 2026 | 9.54M | 15.43% | -1% | 909,746 | 10.5 |
| Sep 30, 2026 | 9.62M | 15.55% | +10% | 1.09M | 8.8 |
| Sep 15, 2026 | 8.77M | 14.18% | +4% | 812,839 | 10.8 |
| Aug 31, 2026 | 8.45M | 13.67% | -1% | 684,634 | 12.3 |
| Aug 14, 2026 | 8.50M | 13.74% | +4% | 636,888 | 13.3 |
| Jul 31, 2026 | 8.18M | 13.53% | +4% | 937,117 | 8.7 |
| Jul 15, 2026 | 7.85M | 12.98% | +9% | 1.30M | 6.0 |
| Jun 30, 2026 | 7.22M | 11.94% | +19% | 1.58M | 4.6 |
| Jun 15, 2026 | 6.07M | 10.04% | +6% | 720,918 | 8.4 |
| May 29, 2026 | 5.74M | 9.50% | +9% | 837,754 | 6.8 |
| May 15, 2026 | 5.28M | 8.74% | +2% | 858,635 | 6.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Kyverna Therapeutics company events
Kyverna Therapeutics filed 18 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Sep 24, 2026.
- Sep 24, 2026AnnouncementShared information with investors. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jul 27, 2026AgreementAs previously disclosed, on July 22, 2023, Kyverna Therapeutics, Inc. entered into that certain Development and Manufacturing Services Agreement (as amended by Amendment #1 thereto on July 24, 2023, the “Prior Agreement”) with ElevateBio Basecamp, Inc., pursuant to which ElevateBio has provided the… Filing
- Jul 9, 2026AgreementAs previously disclosed, on October 31, 2025, Kyverna Therapeutics, Inc. entered into that certain Loan and Security Agreement with Oxford Finance LLC, as collateral agent, and certain lenders from time to time party thereto. Filing
- Jun 2, 2026VoteReported shareholder vote results. Filing
- May 18, 2026LeadershipThe Board of Directors of Kyverna Therapeutics, Inc. appointed Gregory Martini as the Company’s Chief Financial Officer, effective May 18, 2026. Filing
- May 12, 2026ResultsReleased financial results. Filing
- May 4, 2026AnnouncementKyverna Therapeutics, Inc. issued a press release announcing the appointment of Nadia Dac as the Company’s Chief Commercial Officer, effective May 4, 2026. Filing
- Apr 22, 2026AnnouncementShared information with investors. Filing
- Apr 22, 2026AnnouncementShared information with investors. Filing
- Apr 20, 2026AnnouncementShared information with investors. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Feb 24, 2026LeadershipThe board of directors of Kyverna Therapeutics, Inc. appointed Andrew Miller, Ph.D. as a Class III director of the Company, effective immediately. Filing
- Feb 3, 2026LeadershipKaren Walker notified Kyverna Therapeutics, Inc. that she will be retiring from the Company and will cease to serve as the Company’s Chief Technology Officer, effective February 9, 2026. Filing
- Jan 12, 2026LeadershipThe Board appointed Christi Shaw, a current member of the Board, as the Company’s Executive Chairperson of the Board, effective January 12, 2026. Filing
- Dec 18, 2025AgreementKyverna Therapeutics, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Leerink Partners LLC and Morgan Stanley & Co. LLC as the representatives of the several underwriters named therein, relating to the issuance and sale in an underwritten public offering of an aggregate… Filing
- Dec 15, 2025AnnouncementShared information with investors. Filing
- Dec 15, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Kyverna Therapeutics financials
Famous investors that hold KYTX
4 of the 50 well-known investors we track reported holding KYTX in their latest 13F filing. The largest position is Israel Englander's, worth $5.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 826,137 | $5.6M | 0.0% | +29% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 327,821 | $2.2M | 0.0% | -2% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 186,902 | $1.3M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 137,034 | $932K | 0.0% | -7% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named KYTX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | GordonMD Global Investments LP | 13G/A | 7.3% |
| Nov 16, 2026 | GordonMD Global Investments LP | 13G/A | 7.3% |
| Oct 19, 2026 | Orin Hirschman | 13G | 5.9% |
| Oct 19, 2026 | Orin Hirschman | 13G | 5.9% |
Questions about Kyverna Therapeutics, Inc. (KYTX) stock
Who owns the most KYTX stock?
The largest reported owner of Kyverna Therapeutics, Inc. (KYTX) is GordonMD Global Investments LP, with 7.0% of the company. In total, 120 funds and institutions reported holding KYTX at the end of Q2 2026, together about 63% of the shares. See the largest owners.
Are KYTX insiders buying or selling?
In the last 12 months, KYTX insiders reported 1 open-market purchase worth $1000K and 1 sale worth $293K. The latest trade was on Dec 18, 2025. See every trade.
What is the short interest in KYTX?
As of Oct 30, 2026, 9.10M KYTX shares were sold short, 14.7% of the shares outstanding, down 4.7% from the report before. At the average daily volume of 784,251 shares, buying them all back would take about 11.6 trading days (days to cover). See the history.
Which famous investors hold KYTX?
4 of the 50 well-known investors we track reported KYTX in their latest 13F filing, including Israel Englander, Jim Simons, Steve Cohen. The largest position is worth $5.6M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.